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ease, often leading to repetitive hospitalizations because of 
disease exacerbation.2,3 In addition, intestinal Behçet’s disease 
(BD), a chronic, relapsing, inflammatory disorder, presents 
with a variety of bowel symptoms similar to those of IBD, in-
cluding GI bleeding and abdominal pain.4,5 Therefore, the 
treatment approaches for intestinal BD are usually compara-
ble to those for IBD. Traditionally, when patients with IBD or 
intestinal BD are hospitalized because of acute exacerbation, 
fasting is frequently recommended for the purpose of resting 
the bowel, regardless of the disease site or the individual pa-
tient’s condition.
Fasting can reduce inflammation by decreasing the number 
of luminal bacteria and antigens in the colon and can affect 
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Background/Aims: Patients with inflammatory bowel disease (IBD) are usually hospitalized because of aggravated gastroin-
testinal symptoms. Many clinicians empirically advise these patients to fast once they are admitted. However, there has been 
no evidence that maintaining a complete bowel rest improves the disease course. Therefore, we aimed to investigate the effects 
of fasting on disease course in admitted patients with IBD or intestinal Behçet’s disease. Methods: A total of 222 patients with 
IBD or intestinal Behçet’s disease, who were admitted for disease-related symptoms, were retrospectively analyzed. We divided 
them into 2 groups: fasting group (allowed to take sips of water but no food at the time of admission) and dietary group (re-
ceived liquid, soft, or general diet). Results: On admission, 124 patients (55.9%) started fasting and 98 patients (44.1%) started 
diet immediately. Among patients hospitalized through the emergency room, a significantly higher proportion underwent fast-
ing (63.7% vs. 21.4%, P < 0.001); however, 96.0% of the patients experienced dietary changes. Corticosteroid use (P < 0.001; haz-
ard ratio, 2.445; 95% confidence interval, 1.506–3.969) was significantly associated with a reduction in the disease activity score, 
although there was no significant difference between the fasting group and the dietary group in disease activity reduction 
(P = 0.111) on multivariate analysis. Conclusions: In terms of disease activity reduction, there was no significant difference be-
tween the fasting and dietary groups in admitted patients with IBD, suggesting that imprudent fasting is not helpful in improv-
ing the disease course. Therefore, peroral diet should not be avoided unless not tolerated by the patient. (Intest Res 2020;18:85-
95)
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INTRODUCTION 
Inflammatory bowel diseases (IBDs) including UC and CD 
are chronic inflammatory GI disorders of unknown etiology 
that are characterized by recurrent GI symptoms such as diar-
rhea, bleeding, and abdominal pain.1 Patients with IBD pres-
ent with varying clinical symptoms and various clinical cours-
es, ranging from quiescent to acute or chronic refractory dis-
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the anabolic pathway, thus altering the immune system and 
inflammation.6 However, the role of fasting in patients with 
IBD is still not fully understood. Some studies have reported 
that fasting with administration of total parenteral nutrition 
(TPN) has positive effects on nutritional deficits and as peri-
operative nutritional support.7,8 Particularly in patients with 
CD, TPN with bowel rest is recommended for the following 
indications: impossible enteral nutrition (EN), avoidance of 
EN for medical reasons, signs or symptoms of ileus or subileus 
in the small intestine, and presence of intestinal fistulae.9 In 
addition, Müller et al.10 reported that after administering TPN 
for 3 weeks with an additional 9-week course administered at 
home, surgery could be avoided in 25 of 30 patients with CD. 
However, several preliminary studies recently reported that 
EN is more effective than complete bowel rest through fasting 
in patients with severe IBD.11-14 
There is a lack of studies showing how often fasting is being 
recommended for patients with IBD or intestinal BD and 
whether there is a difference in the diet prescription according 
to disease activity. Furthermore, it is still debatable whether 
fasting is helpful in patients with IBD. Therefore, we aimed to 
investigate the effects of fasting in admitted patients with IBD 
or intestinal BD. Moreover, we investigated how frequently 
fasting is actually prescribed and which patients are mainly 
prescribed to fast.
METHODS
1. Patients
Between March 2016 and February 2017, we retrospectively 
reviewed 246 hospitalized patients with IBD or intestinal BD 
at Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea. The diagnosis of UC and CD was based on clini-
cal, endoscopic, histopathologic, and radiologic findings15,16 
and the diagnosis of intestinal BD was made as previously es-
tablished (based on clinical manifestations and colonoscopic 
findings).17 A total of 222 patients were finally enrolled into 
the study. Twenty-four patients were excluded for meeting the 
following exclusion criteria: (1) suspected appearance of any 
other GI diseases such as nonspecific colitis, intestinal tuber-
culosis, or ischemic colitis during the follow-up period; (2) age 
< 18 years; (3) no available clinical data such as disease activi-
ty or clinical records; and (4) could not be followed up during 
the study period. 
We divided the patients into 2 groups according to the diet 
prescription pattern. The fasting group included patients who 
received prescriptions of nil per os (NPO, no oral intake in-
cluding water) or sips of water (SOW, water intake only) at the 
time of admission. The dietary group included patients who 
were prescribed liquid diet (including clear liquid diet [CLD, 
such as water, broth, and plain gelatin] and full liquid diet 
[FLD, consisting of both clear and opaque liquid foods with a 
smooth consistency]), soft diet (foods that are physically soft, 
such as porridge), or general diet. Finally, 124 patients were 
included in the fasting group and 98 patients were included in 
the dietary group. As a retrospective study, the informed con-
sent was waived. This study was performed in accordance 
with the ethical guidelines of the 1975 Declaration of Helsinki 
and approved by the Institutional Review Board of Severance 
Hospital (IRB No. 2019-0453-001).
2. Assessment of Nutrition Status
To assess the nutritional status of hospitalized patients, the 
Severance Nutrition Screening Index18 was used. It includes 
changes in food intake, weight loss, BMI and serum albumin 
level, and is classified into low-risk and high-risk of malnutri-
tion conditions using a cutoff score of 13.5. 
3. Baseline Patient Characteristics
The baseline characteristics of the patients were obtained 
from electronic medical data collected during hospitalizations, 
including patient demographics, comorbid diseases, medica-
tion records at admission, types of nutrition route (e.g., TPN, 
EN, or oral nutrition) at hospitalization, previous bowel opera-
tion, and process of admission (e.g., through the emergency 
room [ER] or outpatient clinic). EN is a method of administer-
ing a nutritional formulation (Encover®: JW Choongwae pharm, 
Seoul, Korea or Harmonilan®: Yungjin Pharm, Seoul, Korea) 
through a Levin tube, gastrostomy, or jejunostomy, bypassing 
the oral cavity and supplying nutrients directly to the GI tract.19 
To evaluate the effects of fasting in hospitalized patients with 
IBD or intestinal BD, we investigated disease activity, laborato-
ry findings such as ESR and CRP levels, and readmission rates.
4. Assessment of Disease Activity
The disease activity of UC was assessed using the Mayo score 
and partial Mayo score. The Mayo score was calculated ac-
cording to the following 4 factors: (1) bowel frequency, (2) 
rectal bleeding, (3) endoscopic findings, and (4) physician as-
sessment. Partial Mayo score was calculated in the same man-
ner but excluding the endoscopic score.20,21 CD disease activity 
was assessed using CDAI.22 To evaluate the disease activity of 
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intestinal BD, we used the disease activity index of intestinal 
BD (DAIBD) based on 8 variables including general well-be-
ing, fever, extraintestinal manifestations, abdominal pain, ab-
dominal mass, tenderness, intestinal complications, and num-
ber of liquid stools. The higher the score, the higher the disease 
activity.23
To analyze the change in disease activity, we calculated the 
disease activity score at the time of admission and after 1 
week. We defined disease activity reduction as having a clini-
cal response after 1 week from admission or before discharge. 
In patients with UC, clinical response was defined as a de-
crease from baseline of ≥ 30% and ≥ 3 points in the Mayo 
score, along with either a rectal bleeding subscore of 0 or 1 or 
a decrease from baseline of ≥ 1 in the rectal bleeding subscore, 
or a reduction by ≥ 2 points and 25% in the partial Mayo score 
compared to baseline.24 In patients with CD, the response to 
treatment was defined as a reduction in CDAI of ≥ 70–100.25 
In patients with intestinal BD, clinical response was defined as 
a decrease in the DAIBD score of ≥ 20 points from the base-
line value.26 
5. Statistical Analysis
Variables were expressed as median (interquartile range 
[IQR]) or number (%). The baseline characteristics were com-
pared using independent Student t-test (or Mann-Whitney 
test) for continuous variables and the chi-square test (or Fish-
er exact test) for categorical variables, as appropriate. We com-
pared whether dietary prescriptions were associated with re-
duced disease activity and readmission. The independent pre-
dictors of reduction in disease activity, ESR, and CRP levels 
were analyzed using Cox regression analysis. Hazard ratios 
(HRs) and the corresponding 95% CIs were calculated. In ad-
dition, factors related to readmission within 3 months were 
analyzed using logistic regression analysis. ORs and the corre-
sponding 95% CIs were calculated. The overall cumulative risk 
rates of disease activity reduction were analyzed using the Ka-
plan-Meier method and compared using the log-rank test. 
Data were analyzed using SPSS software version 25.0 (IBM 
Corp., Armonk, NY, USA). A P-value of < 0.05 was considered 
statistically significant.
RESULTS
1.  Baseline Characteristics of the Fasting and Dietary 
Groups at Hospitalization
The baseline characteristics of the fasting group (NPO or 
SOW) and the dietary group (CLD, FLD, soft diet, and general 
diet) are summarized in Table 1. A total of 222 patients with 
IBD or intestinal BD were hospitalized for disease aggravation 
between March 2016 and February 2017. Among them, 75 
patients had UC (33.8%), 82 patients had CD (36.9%), and 65 
patients had intestinal BD (29.3%). The median age at admis-
sion was 40 years (IQR, 27–51 years), and 48.2% of the pa-
tients were men. There was no significant difference between 
the fasting and dietary groups in sex and age. The median ad-
mission duration was 9 days (IQR, 5–15 days). There was no 
difference in whether the patients were hospitalized through 
the ER (45.0%) or the outpatient clinic (55.0%) at the time of 
admission; however, hospitalization through the ER was sig-
nificantly more frequent in the fasting group (63.7% vs. 21.4%, 
P < 0.001). The most common reason for admission was ab-
dominal pain (39.2%), followed by general weakness (13.1%), 
GI bleeding (11.7%), disease work-up (9.5%), diarrhea (7.7%), 
and fever (7.2%). More patients in the fasting group were hos-
pitalized because of abdominal pain (43.5% vs. 33.7%) or GI 
bleeding (15.3% vs. 7.1%) than those in the dietary group. In 
patients in the dietary group, the most common reason for ad-
mission was abdominal pain, but they were often hospitalized 
because of other GI symptoms such as nausea and vomiting, 
or for changing of medications or disease reassessment. There 
was a difference in the main symptoms between the 2 groups 
(P = 0.029) (Table 1).
Patients in the fasting group more frequently changed their 
diet prescriptions during the hospital stay than did those in 
the dietary group (96.0% vs. 32.7%, P < 0.001). The most fre-
quent dietary prescription among the fasting group of patients 
with dietary changes was soft diet (29.4%), followed by CLD 
(27.7%), FLD (16.0%), SOW (13.4%), and general diet (11.8%). 
In addition, a considerable number of the dietary group pa-
tients simultaneously received TPN (79.6%) or additional EN 
such as Encover® or Harmonilan® (10.2%). However, there was 
no significant difference in BMI, underlying diseases, medica-
tions, and history of bowel operation between the fasting and 
dietary groups (Table 1).
2. Outcomes
We evaluated the laboratory findings including hemoglobin, 
ESR, and CRP levels to estimate disease activity and nutrition-
al status. Laboratory tests were performed at the time of hos-
pital admission and at 1 week after admission and/or before 
discharge. There were no significant changes in the baseline 
and follow-up laboratory findings between the 2 groups (all 
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Table 1. Baseline Characteristics of the Fasting Group and the Dietary Group at Hospitalization 
Variable Total (n=222) Fasting group (n=124)a Dietary group (n=98)b P-valuec
Male sex 107 (48.2) 60 (48.4) 47 (48.0) 0.949
Age at admission (yr) 40 (27–51) 39 (25–49)  40 (31–52) 0.296
Admission days 9 (5–15) 9 (5–15) 8 (5–14) 0.901
Process of admission
   Emergency room 100 (45.0) 79 (63.7) 21 (21.4) <0.001
   Outpatient clinic 122 (55.0) 45 (36.3) 77 (78.6) <0.001
Reasons for admission 0.029
   Abdominal pain 87 (39.2) 54 (43.5) 33 (33.7)
   GI bleeding 26 (11.7) 19 (15.3) 7 (7.1)
   Fever 16 (7.2) 7 (5.6) 9 (9.2)
   Diarrhea 17 (7.7) 11 (8.9) 6 (6.1)
   Screening or work-up 21 (9.5) 9 (7.3) 12 (12.2)
   General weakness 29 (13.1) 16 (12.9) 13 (13.3)
   Othersd 26 (11.7) 8 (6.5) 18 (18.4)
Body weight (kg) 55.0 (48.0–61.0) 55.0 (50.3–62.0) 52.0 (47.0–60.0) 0.685
BMI (kg/m2) 20.1 (18.0–22.5) 20.3 (18.3–22.5) 19.8 (17.6–22.1) 0.290
Type of IBD 0.242
   UC 75 (33.8) 36 (29.0) 39 (39.8)
   CD 82 (36.9) 49 (39.5) 33 (33.7)
   Intestinal Behçet’s disease 65 (29.3) 39 (31.5) 26 (26.5)
Consultation with the nutritional team 65 (29.3) 39 (31.5) 26 (26.5) 0.424
Nutritional status by SNSI 0.709
   Low risk of malnutrition 158 (71.2) 87 (70.2) 71 (72.4)
   High risk of malnutrition  64 (28.8) 37 (29.8) 27 (27.6)
Change in diet prescription 151 (68.0) 119 (96.0) 32 (32.7) <0.001
Medications
   5-ASA 195 (87.8) 111 (89.5) 84 (85.7) 0.389
   Steroids 108 (48.6) 58 (46.8) 50 (51.0) 0.530
   Immunomodulators 89 (40.1) 48 (38.7) 41 (41.8) 0.637
   Methotrexate 18 (8.1) 8 (6.5) 10 (10.2) 0.309
   Anti-TNF agents 48 (21.6) 21 (16.9) 27 (27.6) 0.056
Total parenteral nutrition 191 (86.0) 113 (91.1) 78 (79.6) 0.014
Enteral nutrition 29 (13.1) 19 (15.3) 10 (10.2) 0.261
Previous bowel operation 97 (43.7) 56 (45.2) 41 (41.8) 0.620
Underlying disease
   Hypertension 19 (8.6) 11 (8.9) 8 (8.2) 0.852
   Diabetes 11 (5.0) 5 (4.0) 6 (6.1) 0.476
   Tuberculosis 25 (11.3) 13 (10.5) 12 (12.2) 0.680
   Hematologic disorder 37 (16.7) 16 (12.9) 21 (21.4) 0.091
Values are presented as number (%) or median (interquartile range).
aFasting group: no oral intake including water or water intake only.
bDietary group: liquid, soft, general diet.
cP-value for comparing patients with fasting group and dietary group.
dOthers: nausea, vomiting, medication change, perianal abscess, etc. 
SNSI, Severance Nutrition Screening Index; 5-ASA, 5-aminosalicylic acid.
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P > 0.05). Further, our study population did not show any dif-
ferences in baseline disease activity between the fasting and 
dietary groups (all P > 0.05) (Table 2). There was no significant 
difference in the follow-up scores of disease activity in each 
disease group, such as UC (partial Mayo score, P = 0.953 and 
Mayo score, P = 0.155), CD (P = 0.248), and intestinal BD (P =  
0.239), and in the proportion of patients with a reduction in 
disease activity score between with and without fasting (fast-
ing group 66.1% vs. dietary group 68.4%, P = 0.724). Finally, the 
readmission rate within 3 months after discharge also did not 
show a significant difference between the fasting and dietary 
groups (56.5% vs. 54.1%, P = 0.724). 
3.  Risk Factors Related to Disease Activity and  
Readmission
In the univariate analysis of Cox regression models, corticoste-
roid use (HR, 2.116; 95% CI, 1.507–2.970; P < 0.001) was found 
to be a significant factor in reducing disease activity. Variables 
including male sex, admission through the ER, CD and intesti-
nal BD compared with UC, high initial hemoglobin, and albu-
min levels were negatively associated with reduced disease 
activity score (all P < 0.05) (Table 3). In the multivariate analy-
sis with adjustment for age at admission, medications, body 
weight, albumin, ESR, and CRP levels, corticosteroid use (ad-
justed HR, 2.445; 95% CI, 1.506–3.969; P < 0.001) was found to 
be the only significant factor in reducing disease activity, and 
male sex (adjusted HR, 0.661; 95% CI, 0.441–0.990; P = 0.044), 
Table 2. Outcomes of the Fasting and Dietary Groups
Variable Total(n=222)
Fasting group
(n=124)a
Dietary group
(n=98)b P-value
c
Laboratory findings
   Hemoglobin (g/dL) 11.6 (10.0–13.6) 12.0 (10.0–14.0)  11.1 (10.0–13.0) 0.174
   Initial ESR (mm/hr) 50.5 (26.0–83.8) 48.0 (22.0–84.5)  52.0 (33.0–83.0) 0.525
   Follow-up ESR (mm/hr) 33.0 (15.3–59.0) 10.0 (7.0–23.0)  36.0 (17.5–58.5) 0.562
   Initial CRP (mg/L) 30.5 (5.7–103.7)  23.5 (3.8–104.9)  33.6 (9.0–103.9) 0.754
   Follow-up CRP (mg/L) 6.3 (1.4–23.4) 6.4 (1.2–22.9)  6.1 (1.7–25.8) 0.296
   Initial albumin (g/dL) 3.6 (3.0–4.0) 3.6 (3.0–4.0) 3.6 (3.0–4.0) 0.908
   Follow-up albumin (g/dL) 3.4 (2.8–4.0) 3.5 (2.9–4.0) 3.2 (2.5–3.9) 0.002
Disease activity 
   UC
      Partial Mayo score 6.0 (4.0–7.0) 5.5 (4.0–8.3) 6.0 (3.5–7.0) 0.685
      Mayo score 11.0 (8.0–13.0) 11.5 (9.8–14.3) 10.0 (7.0–12.3) 0.064
   CD 322.0 (236.0–425.0)  308.0 (227.5–399.5)   353.0 (281.5–461.0) 0.065
   Intestinal Behçet’s disease 90.0 (50.0–130.0) 80.0 (50.0–120.0)   80.0 (50.0–120.0) 0.690
Follow-up disease activity
   UC
      Partial Mayo score 3.0 (2.0–5.0) 3.0 (2.0–5.0) 3.0 (2.0–5.5) 0.953
      Mayo score 6.0 (4.0–7.8) 6.0 (4.3–8.0) 4.5 (3.0–6.8) 0.155
   CD 320.5 (257.0–375.3) 319.0 (286.5–393.5)   322.0 (236.0–365.5) 0.248
   Intestinal Behçet’s disease 50.0 (25.0–80.0) 55.0 (27.5–105.0)   40.0 (20.0–60.0) 0.239
DAI reduction 149 (67.1) 82 (66.1) 67 (68.4) 0.724
Readmission 123 (55.4) 70 (56.5) 53 (54.1) 0.724
Values are presented as median (interquartile range) or number (%).
aFasting group: no oral intake including water or water intake only.
bDietary group: liquid, soft, general diet.
cP-value for comparing patients with fasting group and dietary group.
DAI, disease activity index.
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admission through the ER (adjusted HR, 0.638; 95% CI, 0.434–
0.939; P = 0.023), intestinal BD (adjusted HR, 0.397; 95% CI, 
0.233–0.676; P = 0.001) compared with UC, and high initial he-
moglobin level (adjusted HR, 0.906; 95% CI, 0.824–0.998; P =  
0.045) were negative factors. Importantly, the fasting group 
did not show any significant superiority in reducing disease 
activity compared with the dietary group (adjusted HR, 1.376; 
95% CI, 0.929–2.039; P = 0.111) (Table 3). Furthermore, there 
was no significant difference in disease activity reduction be-
tween the fasting and dietary groups in the log-rank curve 
Table 3. Factors Involved in Reducing the Disease Activity Score (Cox Regression Analysis)
Variable
Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value Adjusted HR (95% CI)
Male sex 0.024 0.681 (0.488–0.950) 0.044 0.661 (0.441–0.990)
Age at admission (yr) 0.595 1.003 (0.992–1.014) 0.200 0.990 (0.975–1.005)
Hospital stay (day) 0.838 1.001 (0.989–1.014)
Diet prescription
   Dietary group 1 (reference) 1 (reference)
   Fasting group 0.825 0.964 (0.697–1.334) 0.111 1.376 (0.929–2.039)
Body weight (kg) at admission 0.078 0.985 (0.968–1.002) 0.604 0.994 (0.974–1.016)
BMI (kg/m2) 0.917 0.997 (0.949–1.048)
Process of admission
   Outpatient clinic 1 (reference) 1 (reference)
   Emergency room 0.025 0.684 (0.491–0.954) 0.023 0.638 (0.434–0.939)
Type of IBD
   UC 1 (reference) 1 (reference)
   CD <0.001 0.432 (0.290–0.644) 0.067 0.574 (0.317–1.040)
   Intestinal Behçet’s disease 0.001 0.498 (0.331–0.748) 0.001 0.397 (0.233–0.676)
Underlying disease
   Hypertension 0.845 1.061 (0.587–1.917)
   Diabetes 0.746 0.889 (0.435–1.816)
   Hematologic disorder 0.774 0.936 (0.593–1.475)
Laboratory findings
   Hemoglobin (g/dL) 0.004 0.908 (0.851–0.969) 0.045 0.906 (0.824–0.998)
   Albumin (g/dL) 0.009 0.739 (0.589–0.927) 0.594 0.912 (0.652–1.277)
   ESR (mm/hr) 0.363 1.002 (0.997–1.008) 0.452 1.003 (0.995–1.011)
   CRP (mg/L) 0.392 0.999 (0.997–1.001) 0.148 0.998 (0.995–1.001)
Medications
   5-ASA 0.185 1.451 (0.836–2.518) 0.151 1.597 (0.843–3.025)
   Corticosteroids <0.001 2.116 (1.507–2.970) <0.001 2.445 (1.506–3.969)
   Immunomodulators 0.219 0.811 (0.581–1.132) 0.861 0.964 (0.637–1.459)
   Anti-TNF agents 0.590 0.893 (0.590–1.350) 0.263 0.745 (0.445–1.247)
   Othersa 0.437 1.230 (0.730–2.072) 0.554 1.229 (0.621–2.430)
Nutritional support - -
   TPN 0.422 0.833 (0.533–1.302)
   EN 0.719 0.915 (0.564–1.485)
aOthers: methotrexate, 6-mercaptopurine.
5-ASA, 5-aminosalicylic acid; TPN, total parenteral nutrition; EN, enteral nutrition.
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(P = 0.708) (Fig. 1). 
In addition, we performed a subgroup analysis except for 
patients with abdominal pain and GI hemorrhage (n = 109), 
because it was thought that therapeutic fasting was required 
for these patients regardless of disease activity. There was no 
significant difference in the reduction of disease activity in the 
fasting group (adjusted HR, 1.730; 95% CI, 0.955–3.134; P =  
0.071) when patients with abdominal and GI bleeding were 
excluded at admission compared with diet group. In multivari-
ate analysis, intestinal BD (adjusted HR, 0.353; 95% CI, 0.167–
0.745; P = 0.006) compared with UC was a negative factor, 
while corticosteroids (adjusted HR, 4.757; 95% CI, 2.149–
10.526; P < 0.001) was an important factor in reducing disease 
activity in hospitalized IBD patients (data not shown). More-
over, when we analyzed the predictive factors of CRP level 
change, the factors associated with decreased CRP levels were 
age at admission, albumin, and other medications on multi-
variate analysis (P < 0.05) (Supplementary Table 1). 
The median days to readmission were 61 days (IQR, 21–131 
days). In the logistic multivariate analysis, intestinal BD (ad-
justed OR, 3.263; 95% CI, 1.303–8.171; P = 0.012) compared 
with UC was a significantly different factor related to readmis-
sion. In addition, high initial hemoglobin level (adjusted OR, 
0.841; 95% CI, 0.711–0.995; P = 0.044) was negatively associat-
ed with early readmission. However, the fasting group did not 
show a significant difference in readmission compared with 
the dietary group (Table 4).
DISCUSSION
Although the importance of nutrition and diet is well known 
in patients with IBD,27,28 it remains controversial whether pre-
scribing fasting is helpful in patients hospitalized because of 
symptom exacerbation. Our study shows that fasting is not ef-
fective in decreasing the disease activity and readmission rate 
in patients with IBD or intestinal BD. In addition, we noticed 
that in cases of hospitalization through the ER (n = 79, 63.7%) 
and in patients with abdominal pain (n = 54, 43.5%) or bleed-
ing (n = 19, 15.3%) at admission, the rate of fasting prescription 
was high.
In patients with IBD, diet is associated with disease patho-
genesis, flare-up, and treatment.28-30 Several studies have re-
ported that diet plays a role in altering the immune system to-
gether with the intestinal microbiota in patients with IBD.31-34 
In an etiologic point of view, it is known that Western diets, 
which consist of refined grains, alcohol, salt, oil, meat, fats, 
polyunsaturated fatty acids, omega-6 fatty acids, and fructose, 
and are low in vegetables and fruits, can be considered envi-
ronmental factors promoting inflammation in genetically sus-
ceptible hosts.35,36 In addition, Jowett et al.37 reported that high-
er consumption of meat, eggs, protein, and alcohol is related 
the relapse of UC. Several studies have reported the role of 
FODMAP (fermentable oligosaccharides, disaccharides and 
monosaccharides, and polyols), which could increase GI 
symptoms such as diarrhea, abdominal pain, and bloating in 
patients with IBD.38,39 Dietary treatment is often used, such as 
exclusive and partial EN, specific carbohydrate diet, or gluten-
free diet. Exclusive EN is effective, and according to the Euro-
pean Society for Clinical Nutrition and Metabolism (ESPEN) 
guideline, it is recommended as the first-line therapy to induce 
remission in children and adolescents with acute active CD.40 
However, there is no evidence on the therapeutic benefits of 
an elimination diet and TPN in patients with UC,11 and the use 
of these dietary interventions in adult patients with CD is con-
troversial.41,42 Especially in patients with active IBD, there is no 
“IBD diet” to promote remission in the ESPEN guideline.40 
Although there is no standardized specific IBD diet, several 
guidelines recommend a normal diet or EN, unless the diet is 
not tolerated, in patients with active UC.43,44 Further, a positive 
effect of EN has been reported in patients with active CD.40,45 
Dickinson et al.46 reported a controlled trial of intravenous hy-
peralimentation and total bowel rest for the treatment of acute 
colitis in 38 patients including 27 patients with UC and 9 pa-
tients with CD, and showed that intravenous hyperalimenta-
Fig. 1. Cumulative risk of disease activity reduction between the dif-
ferent diet prescriptions: dietary group and fasting group (Kaplan-
Meier curves). Dietary group: liquid, soft, general diet;  fasting group: 
no oral intake including water or water intake only. 
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tion and bowel rest had no therapeutic effect in acute colitis. 
According to the second Korean guideline and Toronto con-
sensus statements, normal diet or EN is recommended for pa-
tients with UC except for certain extreme cases in which it is 
not possible.43,44 Our study also showed that despite the high 
prescription rates of fasting at the time of hospitalization and 
fasting with TPN in hospitalized patients with IBD, there was 
no additional benefit in the fasting group compared with the 
dietary group. In addition, there was also no significant rela-
tionship between fasting and disease activity according to 
each disease (UC, CD, and intestinal BD). 
In patients with IBD, readmission is an important factor af-
fecting the quality of life, disease burden, and cost of hospital-
ization. Therefore, many studies have investigated the factors 
related to readmission in patients with IBD, such as chronic 
abdominal pain, infection, steroid use, and depression.47,48 
However, our study showed that fasting at admission was not 
associated with a reduction in the readmission rate.
Table 4. Factors Involved in Readmission within 3 Months  
Variable
Univariate analysis Multivariate analysis
P-value OR (95% CI) P-value Adjusted OR (95% CI)
Male sex 0.160 0.674 (0.388-1.169) 0.554 1.249 (0.597-2.612)
Age at admission (yr) 0.002 1.029 (1.010-1.049) 0.119 1.021 (0.995-1.048)
Hospital stay (day) 0.211 1.015 (0.992-1.039)
Diet prescription
   Dietary group 1 (reference)   1 (reference)   
   Fasting group 0.946 0.981 (0.566-1.701) 0.620 1.201 (0.583-2.475)
Body weight (kg) at admission 0.007 0.960 (0.931-0.989) 0.163 0.972 (0.934-1.012)
BMI (kg/m2) 0.306 0.955 (0.874-1.043)
Process of admission
   Out-patients clinic 1 (reference)   1 (reference)   
   Emergency room 0.677 0.890 (0.513-1.543) 0.598 0.823 (0.398-1.699)
Type of IBD
   UC  1 (reference)   1 (reference)   
   CD 0.727 0.883 (0.440-1.773) 0.627 0.771 (0.270-2.203)
   Intestinal Behçet’s disease 0.001 3.183 (1.583-6.402) 0.012 3.263 (1.303-8.171)
Lab findings
   Hemoglobin (g/dL) <0.001 0.784 (0.694-0.886) 0.044 0.841 (0.711-0.995)
   Albumin (g/dL) 0.007 0.576 (0.385-0.863) 0.864 1.056 (0.564-1.980)
   ESR (mm/hr) 0.020 1.010 (1.002-1.019) 0.705 1.002 (0.990-1.015)
   CRP (mg/L) 0.018 1.004 (1.001-1.007) 0.769 0.999 (0.995-1.004)
Medications
   5-ASA 0.949 0.973 (0.423-2.241) 0.431 1.534 (0.529-4.447)
   Corticosteroids 0.469 1.224 (0.708-2.115) 0.233 0.626 (0.290-1.352)
   Immunomodulators 0.035 0.537 (0.302-0.956) 0.700 0.863 (0.409-1.822)
   Anti-TNF agents 0.239 1.478 (0.771-2.832) 0.345 1.520 (0.637-3.627)
   Othersa 0.170 1.857 (0.767-4.499) 0.468 1.618 (0.441-5.937)
Nutritional support - -
   TPN 0.782 0.895 (0.410-1.955)
   EN 0.558 1.269 (0.573-2.810)
aOthers: methotrexate, 6-mercaptopurine.
5-ASA, 5-aminosalicylic acid; TPN, total parenteral nutrition; EN, enteral nutrition.
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To our knowledge, this is the first study to include both pa-
tients with IBD and patients with intestinal BD, and to show 
that dietary status is not related to disease activity and read-
mission. However, our study has several limitations. First, as 
this was a retrospective cohort study based on the clinical re-
cords, and performed in a single tertiary medical center, a se-
lection bias and unmeasured confounding factors may exist. 
However, our medical center is large and has an IBD clinic 
that attends to many patients with IBD or intestinal BD. In ad-
dition, we did not use early EN or partial EN protocols, as 
these are used in pediatric patients. Further, our analysis was 
limited to short-term outcomes because only 1-year inpatient 
data were analyzed. Second, because our analysis was based 
on the diet prescription at the time of admission, it includes a 
shorter fasting time than the fasting period required to rest the 
bowel. However, it can be said our analyzed prescriptions 
were very similar to those used in clinical practice. Therefore, 
further well-designed studies with a large population are 
needed in the future.
In summary, there was no significant difference between 
the fasting and dietary groups in terms of reduction of disease 
activity in hospitalized patients with IBD or intestinal BD. Im-
prudent fasting prescriptions do not help in reducing the dis-
ease activity and readmission rate. Therefore, diet should not 
be avoided in patients with IBD unless it is not tolerated.
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Supplementary Table 1. Factors Involved in Reducing the CRP Levels (Cox Regression Analysis)
Variable
Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value Adjusted HR (95% CI)
Male sex 0.856 0.972 (0.713–1.325) 0.656 1.091 (0.743–1.601)
Age at admission (yr) 0.558 1.003 (0.993–1.013) 0.018 0.982 (0.968–0.997)
Hospital stay (day) 0.007 1.013 (1.003–1.022) 0.520 1.004 (0.991–1.018)
Diet prescription
   Dietary group 1 (reference)   1 (reference)   
   Fasting group 0.469 0.893 (0.657–1.213) 0.213 0.793 (0.551–1.142)
Body weight (kg) at admission 0.363 0.992 (0.976–1.009) 0.503 1.007 (0.987–1.027)
BMI (kg/m2) 0.830 0.995 (0.948–1.043)
Process of admission
   Outpatient clinic 1 (reference)   1 (reference)   
   Emergency room 0.895 0.980 (0.722–1.329) 0.386 1.175 (0.816–1.691)
Type of IBD
   UC 1 (reference)   1 (reference)   
   CD 0.311 0.821 (0.560–1.202) 0.325 0.757 (0.434–1.318)
   Intestinal Behçet’s disease 0.289 1.231 (0.839–1.806) 0.726 1.091 (0.671–1.772)
Underlying disease
   Hypertension 0.140 1.495 (0.876–2.549)
   Diabetes 0.392 0.714 (0.330–1.545)
   Hematologic disorder 0.039 1.490 (1.020–2.176) 0.378 1.232 (0.775–1.959)
Laboratory findings
   Hemoglobin (g/dL) 0.005 0.917 (0.863–0.975) 0.971 1.002 (0.919–1.092)
   Albumin (g/dL) <0.001 0.639 (0.510–0.800) 0.017 0.686 (0.503–0.936)
   ESR (mm/hr) <0.001 1.009 (1.004–1.013) 0.004 1.009 (1.003–1.014)
Medications
   5-ASA 0.995 1.001 (0.642–1.562) 0.598 1.158 (0.671–1.998)
   Corticosteroids 0.036 1.394 (1.021–1.902) 0.855 1.041 (0.675–1.606)
   Immunomodulators 0.024 0.695 (0.507–0.954) 0.259 0.796 (0.536–1.183)
   Anti-TNF agents 0.801 1.047 (0.731–1.501) 0.712 0.921 (0.594–1.428)
   Othersa 0.181 1.378 (0.861–2.204) 0.047 1.906 (1.010–3.598)
Nutritional support - -
   TPN 0.057 1.578 (0.986–2.524)
   EN 0.737 1.086 (0.672–1.753)
aOthers: methotrexate, 6-mercaptopurine.
5-ASA, 5-aminosalicylic acid; TPN, total parenteral nutrition; EN, enteral nutrition.
See “Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?” on page 85-95.
